Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

UPC vs EEIQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UPC Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–3 Matrix Metrics)

UPC Overall Winner 6-Pillar Tally: UPC 3 – 1 EEIQ (2 Tie) Matrix Metrics: UPC 4 – 3 EEIQ

As of Nov 20, 2026, Universe Pharmaceuticals Inc. (UPC) is the stronger overall head-to-head candidate over EpicQuest Education Group International Limited (EEIQ) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). UPC carries a Unified Composite Score of 41.4/100 (SELL) at $1.08 (N/M Forward P/E, -11.8% operating margin), whereas EEIQ carries 39.2/100 (SELL) at $3.11 (N/M Forward P/E, -47.4% operating margin).

  • Growth vs. Quality Trade-Off: UPC earns the overall head-to-head edge with a stronger Unified Composite Score (41.4/100 SELL vs. EEIQ 39.2/100 SELL) and 4.56β · 163% Vol risk profile, whereas EEIQ leads top-line expansion (+16.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although UPC compares more favorably head-to-head, both UPC (41.4/100 SELL) and EEIQ (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: UPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile EEIQ trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 25.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UPC vs EEIQ
UPC NASDAQ Head-to-Head Winner
Universe Pharmaceuticals Inc. Ordinary Shares
Pharmaceutical Preparations
$1.08
-20.59% 1D
Market Cap $6.8M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 4.56β · 163% Vol
Unified Composite Score
41.4 / 100 SELL
Tech 25.0 Fund 53.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 22
RSI-14: 22.2 · SMA20: $1.60 · SMA50: $3.27
EEIQ NASDAQ
EpicQuest Education Group International Limited Common Stock
Services-Educational Services
$3.11
-5.18% 1D
Market Cap $5.4M
TTM Revenue $9.8M
Forward P/E N/M
Beta / 30D Vol -1.80β · 48% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 35.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 25
RSI-14: 25.4 · SMA20: $3.95 · SMA50: $4.25

6-Pillar Scorecard Institutional Category Breakdown (UPC 3 – 1 EEIQ)

Columns: Metric · UPC · EEIQ
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.4x 0.5x
2. Growth & Scale EEIQ
Revenue Growth (YoY) -1.3% +16.8%
Earnings Growth (YoY) -82.0% +0.0%
TTM Revenue (USD) $18M $9.8M
Market Cap $6.8M $5.4M
3. Profitability & Quality UPC
Gross Margin 36.5% 62.5%
Operating Margin -11.8% -47.4%
Net Profit Margin -10.9% -51.1%
Return on Equity (ROE) -3.5% -46.8%
4. Balance Sheet & Cash Flow UPC
Cash Generation (TTM) -$1.6M EBITDA -$4.3M EBITDA
Cash Flow Margin -9.1% EBITDA Mgn -43.2% EBITDA Mgn
Net Cash / Leverage $98.78 Book/Sh · -3.5% ROE $4.84 Book/Sh · -46.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat UPC
OpEx & R&D Intensity 48.3% of Rev ($8.6M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Education & Training Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UPC (4) vs EEIQ (3)
Institutional Metric UPC EEIQ Criterion Row Edge
Market Capitalization
Scale
$6.8M $5.4M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-1.3% +16.8% Higher Growth EEIQ
Operating Margin (TTM)
Profitability
-11.8% -47.4% Higher Margin UPC
Net Profit Margin
Profitability
-10.9% -51.1% Higher Margin UPC
Return on Equity (ROE)
Capital Efficiency
-3.5% -46.8% Higher ROE UPC
52-Week Range Position
Momentum
0% ($1–$18) 24% ($0–$13) Stronger Trend EEIQ
Beta / 30D Volatility
Risk Regime
4.56β · 163% Vol -1.80β · 48% Vol Lower Realized Risk EEIQ
Unified Institutional Score
Composite Signal
41.4 / 100 (SELL) 39.2 / 100 (SELL) Higher Composite UPC
Trailing 12M Revenue (USD)
Operating Scale
$18M $9.8M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
36.5% 62.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.6M EBITDA ($98.78 Book/Sh · -3.5% ROE) -$4.3M EBITDA ($4.84 Book/Sh · -46.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EEIQ +35.61 pp
UPC: -69.58% · EEIQ: -33.97%
3M Horizon EEIQ +91.21 pp
UPC: -79.74% · EEIQ: +11.47%
6M Horizon EEIQ +70.68 pp
UPC: -60.0% · EEIQ: +10.68%
1Y Horizon EEIQ +989.42 pp
UPC: -69.75% · EEIQ: +919.67%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UPC vs EEIQ. Trailing 12-month operating profitability (UPC -11.8% vs EEIQ -47.4%) and valuation multiples (UPC N/M vs EEIQ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

UPC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin36.5%
Op. Margin-11.8%
ROE / Fwd P/E-3.5% · N/M
EEIQ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.8M
Gross Margin62.5%
Op. Margin-47.4%
ROE / Fwd P/E-46.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UPC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EEIQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EEIQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UPC Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $6.8M market capitalization and -11.8% operating margin.
OpEx & R&D Reinvestment 48.3% of Rev ($8.6M)
90D Engineering Disclosures 0 Published
EEIQ Moat Profile Cyclical / Execution-Driven Positioning
Education & Training Services Operator
Competes within the Education & Training Services value chain with $5.4M market capitalization and -47.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UPC vs EEIQ Key Questions & Quantitative Answers

As of Nov 20, 2026, Universe Pharmaceuticals Inc. (UPC) is the stronger overall head-to-head candidate over EpicQuest Education Group International Limited (EEIQ) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). UPC carries a Unified Composite Score of 41.4/100 (SELL) at $1.08 (N/M Forward P/E, -11.8% operating margin), whereas EEIQ carries 39.2/100 (SELL) at $3.11 (N/M Forward P/E, -47.4% operating margin). Growth vs. Quality Trade-Off: UPC earns the overall head-to-head edge with a stronger Unified Composite Score (41.4/100 SELL vs. EEIQ 39.2/100 SELL) and 4.56β · 163% Vol risk profile, whereas EEIQ leads top-line expansion (+16.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although UPC compares more favorably head-to-head, both UPC (41.4/100 SELL) and EEIQ (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: UPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile EEIQ trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 25.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EEIQ leads the Growth & Scale pillar: UPC posts -1.3% YoY revenue growth and -82.0% YoY earnings growth on $18M TTM revenue (36.5% gross margin, -11.8% operating margin), compared with EEIQ at +16.8% YoY revenue growth and +0.0% YoY earnings growth on $9.8M TTM revenue (62.5% gross margin, -47.4% operating margin). On trailing 12-month operating scale, UPC generates $18M in USD-normalized revenue versus $9.8M for EEIQ. In operating R&D and SG&A reinvestment, UPC deploys 48.3% of Rev ($8.6M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EEIQ.

UPC and EEIQ trade at balanced relative valuation multiples. UPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-9.1% EBITDA margin), whereas EEIQ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-43.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UPC (-3.5% ROE) versus EEIQ (-46.8% ROE) capital efficiency.

In options market volatility and institutional positioning, UPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.56β · 163% Vol realized risk). By comparison, EEIQ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.80β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.